{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:13Z","timestamp":1786119313221,"version":"build-2736575974"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1097\/bor.0b013e3282f54d03","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T08:15:15Z","timestamp":1236240915000},"page":"167-172","source":"Crossref","is-referenced-by-count":40,"title":["We can make gout management more successful now"],"prefix":"10.1097","volume":"20","author":[{"given":"Michael A","family":"Becker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saima","family":"Chohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210128","first-page":"321","article-title":"Management of crystal-induced arthropathies","author":"Wortmann","year":"2006"},{"key":"R2-9-20210128","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00002281-200105000-00016","article-title":"Gout: can management be improved?","volume":"13","author":"Schlesinger","year":"2001","journal-title":"Curr Opin Rheumatol"},{"key":"R3-9-20210128","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/art.1780270417","article-title":"Tophaceous gout: a clinical and radiographic assessment","volume":"27","author":"Nakayama","year":"1984","journal-title":"Arthritis Rheum"},{"key":"R4-9-20210128","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1445-5994.2000.tb00857.x","article-title":"The optimal use of allopurinol: an audit of allopurinol use in South Auckland","volume":"30","author":"Stamp","year":"2000","journal-title":"Aust N Z J Med"},{"key":"R5-9-20210128","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.rhu.0000209882.50228.9f","article-title":"Serum urate levels and gout flares: analysis from managed care data","volume":"12","author":"Sarawate","year":"2006","journal-title":"J Clin Rheum"},{"key":"R6-9-20210128","first-page":"233","article-title":"Severe tophaceous gout: characterization of low socioeconomic level patients from Mexico","volume":"24","author":"Vazquez-Mellado","year":"2006","journal-title":"Clin Exp Rheum"},{"key":"R7-9-20210128","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/rheumatology\/keg422","article-title":"Trends in the manifestations of gout in Taiwan","volume":"42","author":"Chen","year":"2003","journal-title":"Rheumatol"},{"key":"R8-9-20210128","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/art.22014","article-title":"Gout and the risk of acute myocardial infarction","volume":"54","author":"Krishnan","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R9-9-20210128","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","article-title":"Independent impact of gout on mortality and risk for coronary heart disease","volume":"116","author":"Choi","year":"2007","journal-title":"Circulation"},{"key":"R10-9-20210128","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/ajkd.2002.33911","article-title":"The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988\u20131994","volume":"40","author":"Kramer","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"R11-9-20210128","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/ncprheum0556","article-title":"The changing epidemiology of gout","volume":"3","author":"Roddy","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"R12-9-20210128","first-page":"2403","article-title":"Epidemiology of gout: is the incidence rising?","volume":"29","author":"Aromdee","year":"2002","journal-title":"J Rheumatol"},{"key":"R13-9-20210128","first-page":"1582","article-title":"Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population","volume":"31","author":"Wallace","year":"2004","journal-title":"J Rheumatol"},{"key":"R14-9-20210128","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/art.20102","article-title":"Quality of care indicators for gout management","volume":"50","author":"Mikuls","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R15-9-20210128","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/ard.2006.055251","article-title":"EULAR evidence based recommendations for gout. Part I: Diagnosis: report of a task force of the Standing committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R16-9-20210128","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence bases recommendations for gout. Part II: Management: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R17-9-20210128","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"R19-9-20210128","doi-asserted-by":"crossref","first-page":"756","DOI":"10.7326\/0003-4819-131-10-199911160-00007","article-title":"Synovial fluid analysis for intercritical gout","volume":"131","author":"Pascual","year":"1999","journal-title":"Ann Intern Med"},{"key":"R20-9-20210128","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","article-title":"Preliminary criteria for the classification of the acute arthritis of primary gout","volume":"20","author":"Wallace","year":"1977","journal-title":"Arthritis Rheum"},{"key":"R21-9-20210128","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/art.1780290610","article-title":"Reproducibility of synovial fluid analyses: a study among four laboratories","volume":"29","author":"Schumacher","year":"1986","journal-title":"Arthritis Rheum"},{"key":"R22-9-20210128","first-page":"2452","article-title":"Outcome measures for acute and chronic gout","volume":"32","author":"Schumacher","year":"2005","journal-title":"J Rheumatol"},{"key":"R23-9-20210128","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s11926-996-0043-1","article-title":"Diet, alcohol, and gout: how do we advise patients given recent developments?","volume":"7","author":"Choi","year":"2005","journal-title":"Curr Rheumatol Rep"},{"key":"R24-9-20210128","first-page":"2429","article-title":"Colchicine prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J Rheumatol"},{"key":"R25-9-20210128","first-page":"1575","article-title":"Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims","volume":"31","author":"Riedel","year":"2004","journal-title":"J Rheumatol"},{"key":"R26-9-20210128","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective","volume":"81","author":"Sarawate","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"R27-9-20210128","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.rdc.2006.02.005","article-title":"Hyperuricemia and associated diseases","volume":"32","author":"Becker","year":"2006","journal-title":"Rheum Dis Clin North Am"},{"key":"R28-9-20210128","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1001\/archinte.165.7.742","article-title":"Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study","volume":"165","author":"Choi","year":"2005","journal-title":"Arch Intern Med"},{"key":"R29-9-20210128","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout","volume":"33","author":"Dalbeth","year":"2006","journal-title":"J Rheumatol"},{"key":"R30-9-20210128","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"R31-9-20210128","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/ard.60.10.981","article-title":"Relation between adverse events associated with allopurinol and renal function in patients with gout","volume":"60","author":"Vazquez-Mellado","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"R32-9-20210128","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/00002512-199813030-00006","article-title":"Gout in the elderly: clinical presentation and treatment","volume":"13","author":"Fam","year":"1998","journal-title":"Drugs Aging"},{"key":"R33-9-20210128","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/ard.50.4.263","article-title":"Investigation and management of gout in the young and the elderly","volume":"50","author":"Dieppe","year":"1991","journal-title":"Ann Rheum Dis"},{"key":"R34-9-20210128","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/archinte.1986.00360230161022","article-title":"The clinical spectrum of gout in women","volume":"146","author":"Lally","year":"1986","journal-title":"Arch Intern Med"},{"key":"R35-9-20210128","first-page":"718","article-title":"Tophaceous gout in patients with renal transplants treated with cyclosporine A","volume":"20","author":"Baethge","year":"1993","journal-title":"J Rheumatol"},{"key":"R36-9-20210128","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1681\/ASN.V115974","article-title":"Renal transplant-associated hyperuricemia and gout","volume":"11","author":"Clive","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"R37-9-20210128","first-page":"272","article-title":"Multicenter longitudinal study of disease characteristics in patients with treatment failure gout [abstract]","volume":"65","author":"Sundy","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R38-9-20210128","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","article-title":"The efficacy of allopurinol and benzbromarone for the control of hyperuricemia: a pathogenetic approach to the therapy of chronic primary gout","volume":"57","author":"Perez-Ruiz","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"R39-9-20210128","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","article-title":"Allopurinol hypersensitivity syndrome: a review","volume":"27","author":"Arellano","year":"1993","journal-title":"Ann Pharmacother"},{"key":"R40-9-20210128","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1081\/NCN-200027372","article-title":"Febuxostat (TMX-67), a novel, nonpurine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers","volume":"23","author":"Becker","year":"2004","journal-title":"Nucleosides Nucleotides Nucl Acids"},{"key":"R41-9-20210128","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s11926-007-0041-y","article-title":"Uricase and other novel agents for the management of patients with treatment-failure gout","volume":"9","author":"Sundy","year":"2007","journal-title":"Curr Rheumatol Rep"},{"key":"R42-9-20210128","first-page":"S680","article-title":"Febuxostat vs allopurinol and placebo in subjects with hyperuricemia and gout: the 28-week APEX study [abstract]","volume":"52","author":"Schumacher","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R43-9-20210128","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","article-title":"Molecular identification of a renal urate-anion exchanger that regulates blood urate levels","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"key":"R44-9-20210128","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0b013e3282f54d03","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:53:07Z","timestamp":1786038787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002281-200803000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e3282f54d03","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}